news
MHRA approves new medicine formulations for HIV prevention
The authorised formulations are a tablet and a long-acting injection used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis (PrEP).
List view / Grid view
cabotegravir
news
European Commission approves long-acting HIV drug option
The first long-acting injectable PrEP option proven superior to daily oral FTC/TDF in reducing HIV acquisition, has been approved in the European Union (EU).
news
NICE approves first long-acting injectable HIV-1 treatment
NICE has published draft guidance recommending cabotegravir, the first long-acting injectable treatment for HIV-1 infection in adults.
article
HIV treatment evolution: drug development to meet the modern needs of patients
In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
news
Collaboration to develop ultra-long acting medicines for HIV
ViiV Healthcare is licencing Halozyme’s Enhanze® drug delivery technology to help develop ultra-long acting versions of its long-acting HIV pipeline products.
news
Long-acting injectable HIV PrEP outperforms commercially available daily pill
Extensive analysis of interim data finds patients given cabotegravir injection had a 66 percent lower incidence of HIV acquisition than those taking Truvada pills.
article
Showcasing a monthly injectable HIV treatment
Janssen’s Brian Woodfall discusses the pharmaceutical company’s research process for their monthly injectable HIV treatment and their predictions for the future of the condition.
news
Clinical trial tests injectable vs oral HIV medications
A new clinical trial will determine if monthly injections of anti-viral drugs are more effective at suppressing the HIV virus than daily pills.
